Much progress has been achieved in unravelling molecular mechanisms, interactions and pathways involved in APOL1 causation of gain of cell injury, and in turn its most prominent ostensible clinical manifestation—kidney disease risk. The gene discussed is APOL1; the disease is kidney disorder.